Molecular diagnostic approach to liver tissue as an ancillary tool for liver histopathology

Seminars in Liver Disease

Volumn 26, Issue 4, 2006, Pages 328-336

  Libbrecht, Louis ^a   Roskams, Tania ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UZLeuven ^*  (Belgium)

Author keywords

Liver diagnosis; Microarray; Molecular diagnosis; Real time reverse transcriptase PCR

Indexed keywords

HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER DISEASE; LIVER TUMOR; MICROSCOPY; MOLECULAR BIOLOGY; MORPHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR DIAGNOSIS;

HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; RNA, VIRAL;

EID: 33750283685     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951600     Document Type: Review

References (73)

1. McSween RNM, Burt AD, Portmann B, Ishak KG. Pathology of the Liver. 4th ed. London: Churchill Livingstone; 2002
2. Crocker J. Demystified: molecular pathology in oncology. Mol Pathol 2002;55:337-347
3. Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut 2006;55:564-568
4. Jansen PLM, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int 2003;23:315-322
5. Ryder SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455
6. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406-412
7. Camps J, Crisostomo S, Garciagranero M, et al. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993;34:1714-1717
8. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44:S19-S24
9. Wilson LE, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006;43:788-795
10. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960
11. Feld JJ, Liang TJ. Hepatitis C: identifying patients with progressive liver injury. Hepatology 2006;43:S194-S206
12. Smith MW, Walters KA, Korth MJ, et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006;130:179-187
13. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444
14. Hayashida K, Daiba A, Sakai A, et al. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2005;3:1253-1259
15. Yeung E, Chung RT. Microarrays and prediction of interferon response in chronic hepatitis C: not yet ready for prime time. Clin Gastroenterol Hepatol 2005;3:1192-1194
16. Kim IJ, Kang HC, Park JG. Evaluation of microarray analysis for predicting treatment responsiveness in patients with chronic hepatitis C viral infection. Gastroenterology 2005;129:1803
17. Grassi G, Pozzato G, Moretti M, Giacca M. Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction. J Hepatol 1995;23:403-411
18. Gervais A, Martinot M, Boyer N, et al. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C: relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001;35:399-405
19. McHutchison. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693
20. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;23:217-226
21. Nunez-Martinez O, De la Cruz G, De Diego A, et al. Liver transplantation for fulminant and subfulminant hepatic failure. Transplant Proc 2003;35:1855-1856
22. Tessier G, Villeneuve E, Villeneuve JP. Etiology and outcome of acute liver failure: experience from a liver transplantation centre in Montreal. Can J Gastroenterol 2002;16:672-676
23. Huang Q, Jin X, Gaillard ET, et al. Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat Res 2004;549:147-167
24. Ulrich RG, Rockett JC, Gibson GG, Pettit SD. Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. Environ Health Perspect 2004;112:423-427
25. Waring JF, Ciurlionis R, Jolly RA, et al. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 2001;120:359-368
26. Inkinen K, Lahesmaa R, Brandt A, et al. DNA microarray-based gene expression profiles of cytomegalovirus infection and acute rejection in liver transplants. Transplant Proc 2005;37:1227-1229
27. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004;78:65-70
28. Cookson S, Doherty DG, Todryk S, et al. Hepatic expression of IL-15 mRNA is associated with liver graft acceptance. Transpl Immunol 2003;11:39-48
29. Flach R, Speidel N, Flohe S, et al. Analysis of intragraft cytokine expression during early reperfusion after liver transplantation using semi-quantitative RT-PCR. Cytokine 1998;10:445-451
30. Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol 1998;15:285-299
31. Vander Borght S, Libbrecht L, Blokzijl H, et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 2005;207:471-482
32. Makhlouf HR, Abdul-Al HM, Goodman ZD. Diagnosis of focal nodular hyperplasia of the liver by needle biopsy. Hum Pathol 2005;36:1210-1216
33. Fabre A, Audet P, Vilgrain V, et al. Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology 2002;35:414-420
34. Chen ZME, Crone KG, Watson MA, et al. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol 2005;29:1600-1608
35. Bioulac-Sage P, Rebouissou S, Cunha AS, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005;128:1211-1218
36. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004;126:1323-1329
37. Paradis V, Bieche I, Dargere D, et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003;124:651-659
38. Zucman-Rossi J, Jeannot E, Van Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-524
39. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3:68-73
40. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2001;193:476-482
41. Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3: S136-S140
42. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34
43. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology 2004;47:191-198
44. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430
45. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005;25:16-27
46. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules and focal nodular hyperplasia-like nodules. Am J Surg Pathol. In press
47. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97
48. Chang HY, Nuyten DSA, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-3743
49. Di Bisceglie AM. Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes? Liver Transpl 2005;11:S10-S13
50. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005;128:1752-1764
51. Wiesner RH. Patient selection in an era of donor liver shortage: current US policy. Nat Clin Pract Gastroenterol Hepatol 2005;2:24-30
52. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159
53. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346
54. Kurokawa Y, Matoba R, Takemasa I, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004;41:284-291
55. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-929
56. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423
57. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-492
58. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006;103:5923-5928
59. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-676
60. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96
61. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416
62. Marsh JW, Finkelstein SD, Schwartz ME, et al. Advancing the diagnosis and treatment of hepatocellular carcinoma. Liver Transpl 2005;11:469-472
63. Libbrecht L, Lee YS, Durnez A, et al. Microvascular invasion in hepatocellular carcinoma is correlated with differentiation grade, tumor diameter and with unsupervised classification based on gene expression patterns. - Abstract book of the EASL/AASLD/JSH monothematic conference on hepatocellular carcinoma; 2005:10
64. Marsh JW, Finkelstein SD, Demetris AJ, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003;9:664-671
65. Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19:101-118
66. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
67. Fattovich G, Llovet JM. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol 2006;44:1013-1016
68. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-527
69. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology 1996;23:1112-1118
70. Suzuki S, Kondo Y, Hirashima N, et al. Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. J Gastroenterol Hepatol 2003;18:1364-1372
71. Roncalli M, Bianchi P, Grimaldi GC, et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000;31:846-850
72. Kim S, Park YM. Specific gene expression patterns in liver cirrhosis. Biochem Biophys Res Commun 2005;334:681-688
73. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-527